WATCH THE RESEARCH
Retatrutide — educational video
Molecular Theory has explored retatrutide across several video revisions. This single guide brings the mechanism and trial claims together so that a headline percentage can be traced to the study that produced it.
A CLEAR FOUNDATION
The basics
What does triple agonist mean?
Retatrutide is one designed peptide acting at receptors for GLP-1, GIP and glucagon. These are three signaling targets, not three ingredients combined in a retail mixture. [1][5]
What do mechanism experiments establish?
The discovery study tested receptor activity and metabolic effects in preclinical models before early clinical assessment. Its mouse results implicated both food intake and energy expenditure; the precise contribution of each pathway to human weight loss is not settled by those experiments. [1]
What does investigational mean here?
Lilly’s current information identifies retatrutide as under clinical investigation and not FDA-approved. Trial findings do not verify a retail product or establish approval for public use. [5]
At a glance
- The 2023 Phase 2 and TRIUMPH-1 Phase 3 findings come from different studies.
- 28.3% is a group estimate under a specified analysis, not an outcome promised to every participant.
- Receptor biology, measured clinical outcomes and regulatory approval are separate questions.
Evidence in this guide: Preclinical mechanism experiments, a published Phase 2 trial, the Phase 3 publication record and the sponsor’s detailed TRIUMPH-1 announcement. Retatrutide remains investigational and is not FDA-approved as of the source check.
Selected sources at a glance
Compare the research context, reported findings and limitations already explained in this guide. These notes are a selected-source summary, not a systematic review.
| Evidence and sources | Who or what was studied? | What was reported? | Interpretation limit |
|---|---|---|---|
| Randomized human trial[2] | Adults with obesity, or overweight and a weight-related condition, without diabetes. | At 48 weeks, the 2023 report gave a mean weight reduction of 24.2% in the 12-mg study group versus 2.1% with placebo. | These are Phase 2 findings over 48 weeks; they are not the later 80-week TRIUMPH-1 result. Study-group identifiers are provided for attribution, not instructions for use. |
| Phase 3 trial; sponsor-reported efficacy estimand[3] | TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and a weight-related comorbidity, without diabetes. | Lilly’s May 21, 2026 report gave 28.3% mean weight reduction at 80 weeks in the 12-mg group versus 2.2% with placebo, using the efficacy estimand. This estimates outcomes if participants remained on study intervention without prohibited weight-management treatments. | Under the treatment-regimen estimand, which includes discontinuation and prohibited-treatment use, the corresponding figures were 25.0% and 3.9%. The analyses answer different questions. These are not head-to-head comparisons with other medicines. |
| Trial reporting and publication record[3][4] | The same Phase 3 research population. | The sponsor reported gastrointestinal adverse events and altered skin sensations among the observed events. The peer-reviewed TRIUMPH-1 paper is linked below as the original publication record. | A favorable average weight result does not establish suitability or safety for every person. The numerical summary above is explicitly attributed to the sponsor report; full-text access to the Phase 3 paper was unavailable during this update. |
The earlier Phase 2 result
- Who or what was studied?
- Adults with obesity, or overweight and a weight-related condition, without diabetes.
- What did the source report?
- At 48 weeks, the 2023 report gave a mean weight reduction of 24.2% in the 12-mg study group versus 2.1% with placebo. [2]
Keep in context
These are Phase 2 findings over 48 weeks; they are not the later 80-week TRIUMPH-1 result. Study-group identifiers are provided for attribution, not instructions for use.
The 28.3% headline in context
- Who or what was studied?
- TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and a weight-related comorbidity, without diabetes.
- What did the source report?
- Lilly’s May 21, 2026 report gave 28.3% mean weight reduction at 80 weeks in the 12-mg group versus 2.2% with placebo, using the efficacy estimand. This estimates outcomes if participants remained on study intervention without prohibited weight-management treatments. [3]
Keep in context
Under the treatment-regimen estimand, which includes discontinuation and prohibited-treatment use, the corresponding figures were 25.0% and 3.9%. The analyses answer different questions. These are not head-to-head comparisons with other medicines.
Read outcomes alongside safety and the original paper
- Who or what was studied?
- The same Phase 3 research population.
- What did the source report?
- The sponsor reported gastrointestinal adverse events and altered skin sensations among the observed events. The peer-reviewed TRIUMPH-1 paper is linked below as the original publication record. [3][4]
Keep in context
A favorable average weight result does not establish suitability or safety for every person. The numerical summary above is explicitly attributed to the sponsor report; full-text access to the Phase 3 paper was unavailable during this update.
PUT IT TOGETHER
Common questions
Does the triple mechanism prove three separate weight-loss effects in humans?
No. Receptor activation describes the research approach. Preclinical pathway findings do not isolate how much each pathway contributes to the overall human outcome. [1]
Is retatrutide FDA-approved?
No, according to the current developer information checked October 23, 2026. This guide describes investigational research. [5]
Key terms, simply explained
- Agonist
- A substance that activates a receptor.
- Placebo
- A comparison intervention without the studied active medicine.
- Estimand
- The treatment effect a study’s analysis is designed to estimate, including how events such as stopping treatment are handled.
- Mean
- An average across a group, not a guarantee for an individual.
- Phase 3
- A later clinical development stage evaluating efficacy and safety in a defined population.
CHECK THE ORIGINALS
Sources and reading notes
Use these links to read the original record. A paper’s title describes the authors’ study; it is not a claim about a product sold by GreysProtocol.
Coskun et al. (2022), Cell Metabolism (opens in a new tab)
LY3437943: from discovery to clinical proof of concept
Original translational research · Indexed abstract checked; preclinical mechanism findings distinguished from clinical outcomes.
DOI: 10.1016/j.cmet.2022.07.013
Jastreboff et al. (2023), New England Journal of Medicine (opens in a new tab)
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Peer-reviewed randomized trial · Indexed trial record and abstract results checked; not a full-paper critical appraisal.
DOI: 10.1056/NEJMoa2301972
Eli Lilly (May 21, 2026), TRIUMPH-1 results announcement (opens in a new tab)
Phase 3 weight results, efficacy and treatment-regimen estimands
Sponsor report of randomized trial results · Results table, estimand definitions and adverse-event summary checked. Sponsor report is distinguished from independent review.
Jastreboff et al. (2026), New England Journal of Medicine (opens in a new tab)
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Peer-reviewed Phase 3 publication record · Publication title and DOI verified in indexed records. Full text was inaccessible; numerical details above are sourced to the sponsor report.
DOI: 10.1056/NEJMoa2604169
Eli Lilly, What to know about retatrutide (opens in a new tab)
Development and regulatory-status information
Developer information, updated September 2026 · Current investigational and FDA-approval status checked October 23, 2026.
Continue reading
Explore the foundations and examples of peptide research. Each guide explains its own evidence and limitations.
